Adenovirus-mediated gene transfer in the ovine pituitary gland is associated with hypophysitis.
Gene therapy for pituitary disease requires evaluation for safety as well as efficacy. We have reported results of adenovirus-mediated gene transfer using the sheep as a large animal model that allows longitudinal evaluation of hormone secretion and have confirmed high levels of transgene expression up to 7 days after direct stereotaxic injection into the pituitary gland. Here we report the results of detailed histological examination of the pituitary glands from animals injected with two recombinant adenoviruses expressing the beta-galactosidase marker gene, or with saline vehicle to control for the potential tissue-disruptive effect of the injection volume itself. Pituitaries injected with saline showed no evidence of inflammatory response apart from occasional minor foci of apoptosis. In all other respects they were indistinguishable from normal uninjected control pituitary glands. Glands injected with recombinant adenoviruses containing either the hCMV-beta-gal or the hPRL-beta-gal transgene, on the other hand, displayed variable degrees of inflammatory response, with periglandular fibrosis, lymphocytic infiltrate and venulitis in almost all cases. Focal necrosis and/or apoptosis was noted in six of nine cases. In summary, we have found evidence of severe inflammatory reaction within the first seven days of adenovirus injection, amounting to significant hypophysitis. The histological extent of this reaction has not previously been recognised by studies of the efficacy of gene transfer in rodents, and was underestimated by immunocytochemical studies of hormone and transgene expression. The findings emphasise the need for careful evaluation of the safety of endocrine gene therapy, and for caution with the dose of vector used.
Davis
J R E
JR
Endocrine Sciences Research Group, Faculty of Medicine, University of Manchester, Manchester, UK. julian.davis@man.ac.uk
McMahon
R F T
RF
Lowenstein
P R
PR
Castro
M G
MG
Lincoln
G A
GA
McNeilly
A S
AS
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D005260:Female; D015316:Genetic Therapy / Q000009:adverse effects* / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007249:Inflammation; D007267:Injections; D023421:Models, Animal; D009336:Necrosis; D010902:Pituitary Gland / Q000276:immunology* / Q000473:pathology; D011388:Prolactin / Q000235:genetics; D012756:Sheep; D014162:Transfection / Q000379:methods*; D001616:beta-Galactosidase / Q000235:genetics
D011388:Prolactin; D001616:beta-Galactosidase